Phage therapy of pulmonary infections.
Phage therapy of pulmonary infections.
复制标题
DOI：
10.1080/21597081.2015.1020260
复制
发表时间：
2015-01
期刊：
影响因子：
--
通讯作者：
Abedon ST
中科院分区：
文献类型：
--
作者：
Abedon ST
人们普遍认为，噬菌体相关现象是100年前Twort在1915年首次明确观察到的。这是独立其次是补充意见的d'Hérelle在1917年。D'Hérelle对噬菌体现象的理解似乎直接导致了在各种环境中，包括医疗和农业中，细菌作为抗菌剂的发展。噬菌体用于对抗讨厌的细菌似乎特别有用，其中靶是足够成问题的，存在适当的杀菌剂，并且替代方法缺乏有效性、可用性、安全性或成本效益等。噬菌体作为抗菌剂的开发已经是最强的，特别是当抗生素已经不太可用或有用时，例如，例如用于治疗由抗真菌细菌引起的慢性感染。一种相对未充分开发的或至少没有高度报道的使用呼吸道疾病作为治疗剂的用途是对抗肺和相关组织的细菌感染。这些感染在它们的病因、表现方面以及在噬菌体递送的潜在策略方面是多样的。在这里，我回顾了考虑肺部和肺部相关感染的噬菌体治疗的文献，重点是临床治疗的报告，沿着使用动物模型的肺部感染的实验治疗。
It is generally agreed that a bacteriophage-associated phenomenon was first unambiguously observed one-hundred years ago with the findings of Twort in 1915. This was independently followed by complementary observations by d'Hérelle in 1917. D'Hérelle's appreciation of the bacteriophage phenomenon appears to have directly led to the development of phages as antibacterial agents within a variety of contexts, including medical and agricultural. Phage use to combat nuisance bacteria appears to be especially useful where targets are sufficiently problematic, suitably bactericidal phages exist, and alternative approaches are lacking in effectiveness, availability, safety, or cost effectiveness, etc. Phage development as antibacterial agents has been strongest particularly when antibiotics have been less available or useful, e.g., such as in the treatment of chronic infections by antibiotic-resistant bacteria. One relatively under-explored or at least not highly reported use of phages as therapeutic agents has been to combat bacterial infections of the lungs and associated tissues. These infections are diverse in terms of their etiologies, manifestations, and also in terms of potential strategies of phage delivery. Here I review the literature considering the phage therapy of pulmonary and pulmonary-related infections, with emphasis on reports of clinical treatment along with experimental treatment of pulmonary infections using animal models.